Implement the Screening Program for Thyroid Cancer Sample Clauses

Implement the Screening Program for Thyroid Cancer. During the past year, the most important accomplishment of the CCIP was the significant increase in the number of children screened. As of May 18, 2001, a total of 53,702 children have been screened by ultrasound and 53,333 by the Children's Depression Inventory (CDI) in the four target oblasts. A summary of screening activity to date is provided in Table One. TABLE 1: SUMMARY OF CCIP OBLAST SCREENING ACTIVITIES OBLAST TOTAL SCREENED : THYROID THYROID ABNORMALITIES IDENTIFIED TOTAL SCREENED: PSYCHOSOCIAL PSYCHOSOCIAL ABNORMALITIES IDENTIFIED VOLYN 15,818 1,290 (8.2%) 15,810 2,031 (12.8%) RIVNE 12,242 712 (5.8%) 11,882 2,393 (20.1%) CHERKASSY 11,635 722 (6.2%) 11,635 1,479 (12.7%) ZHYTOMYR 14,007 1,160 ( 8.3%) 14,006 1,705 (12.5%) TOTAL 53,702 3,884 (7.2%) 53,333 7,608 (14.3%) The increase in the number of children screened is vividly demonstrated in the graph shown below (Attachment B). Note the acceleration in the month of August 2000 which coincided with CCIP's introduction of "performance incentive" payments to the mobile teams' staff. To date, three children (one each from Cherkassy, Rivne and Volyn Oblasts) have been found to have thyroid cancer. A fourth child from Rivne who was attending a summer camp, was diagnosed with possible thyroid cancer. After he returned to his home, however, which was outside of the targeted raions in Rivne, the UAHC did not receive further information on his status. Our Rivne UAHC secretary has been asked to check on his condition and what treatment was provided. The percentage of children with benign and malignant abnormalities (where normal = 0.1 percent) is consistent with the percentage reported from radiation contaminated areas in other countries. The incidence of three children with thyroid cancer among 53,702 screened is considerably higher than the 1:1-2 million incidence among populations not exposed to nuclear fallout. Table 2 shows the number of thyroid abnormalities identified. The thyroid is considered abnormal when an ultrasound image shows solitary thyroid nodules, multiple thyroid nodules or other abnormalities such as diffuse enlargement, absent lobe, ectopic location of the thyroid or abnormal shape of the gland. Of particular interest is the number of children with single and multiple nodules. Endocrinologists have recently suggested that these lesions may be precancerous. For this reason, we believe that all children we have screened who have been found to have nodules will have to be screened periodic...
Sample 1
AutoNDA by SimpleDocs
Implement the Screening Program for Thyroid Cancer. As of April 30, 2000, a total of 7,938 children had been screened by ultrasound and 7,893 by the CDI in the four target oblasts. A summary of screening activity to date is provided in Table One. TABLE 1: OBLAST SCREENING SUMMARY OBLAST TOTAL SCREENED: THYROID THYROID ABNORMALITIES TOTAL SCREENED: PSYCHOSOCIAL PSYCHOSOCIAL ABNORMALITIES VOLYN 2569 199 (7.8%) 2569 136 ( 5.3%) RIVNE 2623 92 (3.5%) 2578 402 (15.6%) CHERKASSY 2080 106 (5.1%) 2080 344 (16.5%) ZHYTOMYR 666 99 (14.9%) 666 104 (15.6%) TOTAL 7938 496 (6.2%) 7893 986 (12.5%) The data presented in this table are being reexamined to ensure the four oblasts have standardized their weekly screening reports. A revised table will be submitted to USAID in June if the above numbers change. One child in Volyn Oblast was found to have thyroid cancer. The percentage of children with abnormalities (where normal = 0.1 percent) is consistent with the percentage reported from radiation contaminated areas in other countries. The incidence of one child with thyroid cancer among 7938 screened is considerably higher than the one in one to two million incidence among normal populations. The total number of children screened to date is lower than we had originally estimated. There are a number of reasons for these lower numbers including: • Delays in obtaining the screening equipment; • Winter weather hindering travel to the affected rural areas; • A flu outbreak closed schools in a number of raions for several weeks; • The necessity of signing an amendment to our MOU with Zhytomyr Oblast Health Administration, which delayed the start of screening in that oblast; • Although schools are informed of the mobile unit’s schedule, in some instances, children are not available for screening when the mobile unit arrives. They may be out of school due to illness or for other reasons; • Ultrasonography takes between 5 and 7 minutes per child. This limits the total number that can be screened in one day; and • When only one mobile psychologist was assigned to the team, they were not able to conduct both the CDI and individual interviews with all children examined by ultrasound. This problem has been rectified as now two psychologists are assigned to each mobile team. The combined effect of these problems has proven to slow down the screening process. We are continually working with the UAHC Directors and staff to improve the efficiency of the screening process.
Sample 1
Implement the Screening Program for Thyroid Cancer 
Sample 1

Related to Implement the Screening Program for Thyroid Cancer

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Develop programs 1) The Employer will develop and implement health promotion and health education programs, subject to the availability of resources. Each Appointing Authority will develop a health promotion and health education program consistent with the Minnesota Management & Budget policy. Upon request of any exclusive representative in an agency, the Appointing Authority shall jointly meet and confer with the exclusive representative(s) and may include other interested exclusive representatives. Agenda items shall include but are not limited to smoking cessation, weight loss, stress management, health education/self-care, and education on related benefits provided through the health plan administrators serving state employees.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Program Evaluation The School District and the College will develop a plan for the evaluation of the Dual Credit program to be completed each year. The evaluation will include, but is not limited to, disaggregated attendance and retention rates, GPA of high-school-credit-only courses and college courses, satisfactory progress in college courses, state assessment results, SAT/ACT, as applicable, TSIA readiness by grade level, and adequate progress toward the college-readiness of the students in the program. The School District commits to collecting longitudinal data as specified by the College, and making data and performance outcomes available to the College upon request. HB 1638 and SACSCOC require the collection of data points to be longitudinally captured by the School District, in collaboration with the College, will include, at minimum: student enrollment, GPA, retention, persistence, completion, transfer and scholarships. School District will provide parent contact and demographic information to the College upon request for targeted marketing of degree completion or workforce development information to parents of Students. School District agrees to obtain valid FERPA releases drafted to support the supply of such data if deemed required by counsel to either School District or the College. The College conducts and reports regular and ongoing evaluations of the Dual Credit program effectiveness and uses the results for continuous improvement.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!